Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | MLYCD | O95822 | 3/20 | 0.65 |
| ▸ | RORC | P51449 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5352362 | 0.85 | TSHR (0.56) | SMN1; SMN2MLYCDTSHRTP53 | |
| SCHEMBL134581 | 0.84 | TP53 (0.66) | TSHRTP53 | |
| SCHEMBL6843427 | 0.83 | SMN1; SMN2 (0.62) | SMN1; SMN2MLYCDRORCTP53 | |
| SCHEMBL2081375 | 0.81 | SMN1; SMN2 (1.00) | SMN1; SMN2MLYCDRORC | |
| SCHEMBL687878 | 0.80 | TSHR (0.79) | TSHR | |
| SCHEMBL3434346 | 0.79 | SMN1; SMN2 (0.71) | SMN1; SMN2MLYCDRORCNR1H3NR1H2 | |
| SCHEMBL9722104 | 0.79 | TSHR (0.61) | SMN1; SMN2TSHR | |
| SCHEMBL11582431 | 0.78 | TP53 (0.57) | TSHRTP53 | |
| SCHEMBL2079990 | 0.77 | SMN1; SMN2 (0.69) | SMN1; SMN2MLYCDRORCNR1H3 | |
| SCHEMBL11626027 | 0.77 | SMN1; SMN2 (0.69) | SMN1; SMN2MLYCDRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | ME2, PC, ACACA | SMN1; SMN2 2021/4885MLYCD 6/4885RORC 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.